Editorial: Importance of botulinum toxin for prevention of migraine

Expert Review of Neurotherapeutics

Volumn 10, Issue 3, 2010, Pages 339-340

  Freitag, Frederick G ^a,b,c,d  

^a DIAMOND HEADACHE CLINIC   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d MIDWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; MUSCLE RELAXANT AGENT;

BLEPHAROSPASM; CEREBRAL PALSY; CERVICAL DYSTONIA; CHILDHOOD DISEASE; DRUG WITHDRAWAL; EDITORIAL; HEADACHE; HEMIFACIAL SPASM; HUMAN; MIGRAINE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

BOTULINUM TOXIN TYPE A; HUMANS; MIGRAINE DISORDERS; NEUROMUSCULAR AGENTS;

EID: 77649289633     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.11     Document Type: Editorial

References (4)

1. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol. Head Neck Surg. 123, 669-676 (2000).
2. Dodick DW, Mauskop A, Elkind AH et al. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45, 315-324 (2005).
3. Mathew NT, Kailasam J, Meadors L. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache 48, 194-200 (2008).
4. Burstein R, Dodick D, Silberstein S. Migraine prophylaxis with botulinum toxin A is associated with perception of headache. Toxicon 54, 624-627 (2009).